SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

Fueled by a recent congressional stock purchase, BigBear.ai is trending as investors speculate on potential government contracts, drawing comparisons to Palantir. The community is actively discussing chart patterns and a possible short squeeze, with bullish investors focusing on AI-driven security solutions. Chatter suggests anticipation for significant gains amidst growing interest in AI for defense and security.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as it attempts to break out of a monthly range, spurring discussions about a potential squeeze due to its high short interest. Community members are debating its undervaluation and future prospects, particularly in light of Bitcoin's price movements and potential AI integration. Some investors express frustration with the stock's performance compared to sector peers, while others remain optimistic about a significant upward move.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

TURB is trending due to a recent surge, with community members actively discussing its potential for a continued squeeze and comparing it to other high-flying stocks. The stock experienced a notable run, and traders are weighing its potential for further upside against concerns of a possible pullback. Some see the stock as a play in the energy sector, while others debate the long-term prospects.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential for a short squeeze, given its high short interest and days to cover. Community members are actively debating its valuation relative to peers like $IREN, along with potential catalysts like a pivot towards HPC/AI and a possible data center announcement. Chatter also includes discussions around new leveraged ETFs and analyst price targets.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo ($MLGO) is trending amid community discussions about its volatility and potential for a short squeeze, with some pointing to its history of large price swings. Community members are debating its valuation, the impact of potential dilution, and upcoming earnings. Some traders are comparing it to other volatile stocks, while others are closely watching volume and short interest.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending as the company's latest earnings report and forward guidance exceeded expectations, driving optimism about its growth prospects. The community is discussing the potential for new locations and sustained revenue growth, while analysts are updating their price targets, adding to the bullish sentiment. Some are comparing BROS to other coffee companies, noting its ability to grow and compete in the current consumer environment.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending due to the launch of new low-testosterone treatment plans, including an exclusive oral therapy, sparking a mix of excitement and skepticism. While some see this as a major growth catalyst and potential short squeeze opportunity, others express concerns about market competition and potential regulatory scrutiny, particularly regarding advertising practices. The community is actively debating whether this move will propel HIMS to new heights or if it's overhyped.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to a potential short squeeze, fueled by its small float and significant insider/institutional ownership. Community members are actively discussing strategies to push the price higher, aiming to force shorts to cover their positions. Technical analysis suggests bullish targets, with some traders comparing it to other recently squeezed stocks with similar float characteristics.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors discuss upcoming warrants and their potential impact on shorts, with some anticipating a significant squeeze. Community members are speculating about the stock's potential and whether Ryan Cohen might announce a catalyst. Discussions also involve comparing GME to other meme stocks and analyzing technical indicators.

Trump For President

The TRUMP.X crypto is trending amid discussions about its potential connection to political events and figures, including Trump's policies and public appearances. Some community members express concerns about its performance compared to other cryptocurrencies like Bitcoin and Etherium, while others speculate on future price movements and potential investment opportunities. There are also discussions around the launch of a new DeFi token by the Trump family.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of...

Retail&nbsp;trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral’, citing the sudden resignation of Vinay Prasad, former head of the FDA’s biologics division, as a key development that could improve the outlook for RP1, the company’s lead oncolytic immunotherapy candidate.The stock more than doubled Wednesday, closing up 101% at $7.55.Cantor analyst Li Watsek said the FDA’s Complete Response Letter (CRL) issued on July 22 for RP1 in combination with nivolumab was likely influenced by senior leadership, possibly Prasad, overruling the agency’s review team.&nbsp;Watsek sees Prasad’s exit as “removing a major obstacle” and believes the odds of RP1 receiving accelerated approval have “greatly improved.” Cantor expects Replimune shares could return to pre-CRL levels above $12 if the decision is overturned.BMO Capital analyst Evan Seigerman&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">also said</a> Prasad’s departure is a net positive for the biopharma sector, noting that a new FDA biologics director is “likely to be more permissive of innovation.” While BMO remains uncertain whether RP1 will be reconsidered, the firm expects shares to rally meaningfully on the change.<a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">Prasad stepped down</a> just two months into his role leading the FDA’s biologics division, after facing growing backlash over how he handled Sarepta’s Elevidys, the only approved gene therapy for Duchenne muscular dystrophy.Earlier this month, Prasad and FDA Commissioner Marty Makary asked Sarepta to halt shipments of Elevidys after three children who received the therapy died, including two from liver failure.&nbsp;The move ignited backlash from patient advocates and conservative media, who slammed the agency for standing in the way of what many families see as a last hope for kids battling a fatal condition.&nbsp;Replimune stated that the CRL for RP1 cited the Ignyte Phase 1/2 trial as lacking the rigor to support approval, due to heterogeneity in the patient population and concerns regarding the confirmatory study design. No safety issues were raised.&nbsp;The company plans to request a Type A meeting with the FDA to explore a path forward for accelerated approval.CEO Sushil Patel expressed surprise at the CRL, noting that the issues raised&nbsp;had not been&nbsp;discussed during the mid- and late-cycle reviews. RP1, engineered from a herpes simplex virus, is designed to directly kill tumors and trigger a systemic immune response.&nbsp;It’s the lead program in Replimune’s proprietary RPx platform, which the company believes can work&nbsp;independently or&nbsp;in conjunction with other cancer therapies.On Stocktwits, retail sentiment for Replimune was ‘extremely bullish’ late Wednesday amid a 1,038% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/REPL">Replimune’s stock</a> has declined nearly 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail buzz around Replimune Group (REPL) surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral.’ (Photo credit: Getty Images)

Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval

Analysts believe the resignation of a top FDA official could lead to a reversal of the melanoma drug rejection, which was based on trial design concerns.

Equity

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

Replimune, Inc. (<a class="mention" data-mention="$REPL" data-symbol-id="REPL" href="https://stocktwits.com/symbol/REPL" target="_blank">$REPL</a>) shares spiked higher in Thursday’s after-hours session after the small-cap biopharma developing oncolytic immunotherapies, provided a key regulatory update for its combo therapy candidate to treat skin cancer, lifting retail sentiment.The Woburn, Mass.-based clinical-stage biopharma said after the market closed that it has submitted a biologic license application (BLA) for RP1, aka vusolimogene oderparepvec, -&nbsp; its lead immulytic product candidate, in combination with Bristol-Myers Squibb Co.’s (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">$BMY</a>) Opdivo, for advanced melanoma patients who have been previously treated with anti-PD1 therapies.Anti-PD1 therapy is currently the standard of care for several types of cancer.RP1 is based on a proprietary new strain of the Herpes simplex virus engineered to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.The regulatory filing has been done under the accelerated approval pathway, which expedites approval for drugs to treat unmet needs based on a “surrogate endpoint,” rather than a direct measure of clinical benefit.The combo therapy also received FDA’s breakthrough therapy designation (BTD) based on the safety and clinical activity observed in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.A BTD designation is meant to expedite drug development for treating life-threatening and serious medical conditions by allowing increased FDA interactions and intensive guidance from the agency.Sushil Patel, CEO of Replimune, said, "Today is an important milestone for Replimune and for the melanoma community as we are one step closer to having another potential treatment available for patients who have limited options after progressing on anti-PD1 containing regimens.”The biopharma said patients are&nbsp;currently being enrolled for the confirmatory late-stage study, dubbed IGNYTE-3 trial.<figure class="image"><a href="https://stocktwits.com/symbol/REPL"><img style="aspect-ratio:635/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/repl_sentiment_0c14327fe5.png" alt="repl-sentiment.png" width="635" height="137"></a><figcaption>REPL sentiment and message volume November 22, 2024, as of 3:25 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment inflected higher from ‘neutral’ (46/100) a day ago to ‘bullish’ (57/100), with message volume rising to ‘extremely high.’Replimune stock climbed 19.37% in Thursday’s after-hours session to $13.19, its highest level in a little over a year. The stock has gained 31.08% for the year-to-date period.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/reddit-stock-drops-on-insider-sales/cJI5NjxRXx">Reddit Stock Pulls Back From Record Highs After Tencent Cuts Stake Yet Again: Retail Turns Apprehensive</a>

Replimune's RP1+Opdivo combo therapy gets breakthrough therapy designation. 

Replimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat

Replimune’s lead asset RP1 is based on a proprietary new strain of Herpes simplex virus engineered to maximize tumor killing potency.

Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patientsSAN DIEGO, April 07, 2024...

Replimune Group announces inducement grants under Nasdaq listing rule

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...

Replimune Group (REPL, $8.24) price moved above its 50-day Moving Average on March 27, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Replimune Group announces CEO transition

Replimune Group announces CEO transition...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '25	-$0.77	--	--	N/A
Q1 '25	-$0.79	-$0.95	-19.57%	MISSED
Q4 '24	-$0.72	-$0.82	-14.42%	MISSED
Q3 '24	-$0.71	-$0.79	-11.88%	MISSED
Q2 '24	-$0.82	-$0.68	17.41%	BEAT

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '25

Historical Earnings

Latest REPL News

REPL Replimune Group Inc